



THE 2015 CONTROLLING CANCER SUMMIT

AGENDA



**12th-14th May 2015
London, UK**

EuroSciCon 

With plenty of opportunity for networking and debate, this informal international meeting will bring you up to date with current research and thinking regarding cancer screening, prevention and treatment. Presenters will include Clinicians, Academics and members of the Pharmaceutical industry and we encourage presentations from the wide spectrum of cancer research, development and healthcare professionals.

This event has [CPD accreditation](#)

This is a draft agenda
The agenda will be finalised two weeks before the event
www.regonline.co.uk/cancer2015
Hashtag: #cancer2015

Contents

Agenda (Talk times include 5 – 10 minutes for questions)	5
Day 1: Diagnosis, Staging and Assessment	5
Introduction by the Chair	5
Cell-mediated anti-cancer immunotherapy; targeting chemotherapy-resistant malignant cells with personalized immunotherapy mediated by autologous and allogeneic cells	5
Early detection of oral carcinogenesis: the biological fundamentals of in vivo optical imaging.....	5
Oral Presentations	5
Cancer Causation and Risk Communication: The gap between cancer knowledge and community perceptions.....	5
Prognostic value of repeat testing in population screening for CRC - for optimizing efficacy	5
Lung Cancer CT Screening : Time for implementation?.....	5
Novel methods to assess and support older people with cancer; Comprehensive Care for Older People with Cancer (COCOC)..	5
Day 2 Session 1: Treatment.....	6
Introduction by the Chair.....	6
1st line chemotherapy in treatment of mCRC: FOLFIRI vs FOLFIRI+bevacizumab - single institution experience.....	6
Second line treatments in advanced non-small cell lung cancer.....	6
Day 2 Session 1: Quality of life	6
Oral presentations	6
14:40 – 14:55 MEASURING THE PREVALENCE, SEVERITY AND QUALITY OF LIFE PREDICTORS OF CONCURRENT SYMPTOMS IN CANCER PATIENTS IN JORDAN	6
Day 3: Therapeutics	7
Introduction by the Chairs	7
From cancer genotype to phenotype by proteomics	7
Vitamin D binding protein-based immunotherapy leads to reversal of the neoplastic phenotype and suppression of oncogene expression.	7
Oral Presentations	7
Discussion session.....	7
ErbB-targeted CAR T-cell immunotherapy of cancer: a strategy to maximize the window of therapeutic opportunity.....	7
Overcoming Mechanisms of Therapeutic Resistance in Advanced Castration Resistant Prostate Cancer	7
Oral Presentations	7
Talk title to be confirmed.....	7
Androgen Deprivation Therapy for Prostate Cancer	7
About the Speakers	8
Day 1.....	8
Shimon Slavin,	8
Jorge Pascual,.....	8
Bernard W. Stewart,.....	8
Pavel Elsakov,.....	8
Day 2.....	8

Richard Gray,.....	8
Mukesh Verma,	8
Zhixiang Wang,	9
Peter Creighton Elwood,	9
Mircea Dediu,	9
Simonetta Monti,	9
Robert Thomas,	9
Gwendolyn P. Quinn,	9
Graeme Melville,	9
Day 3	10
Janne Lehtio,	10
Marco Ruggiero,	10
Nives Pećina-Šlaus,	10
John Maher,	10
Natasha Kyprianou,	10
Patricia Tak Hing Tai	10
Discussion Sessions.....	11
Session breaks	11
Lunch	11
• All the chicken in our lunch buffet is Halal	11
• We have a number of dishes that are gluten free	11
• We have a range of vegetarian dishes which are separated from the meat and fish dishes	11
Frequently asked questions about our events	11
Is the delegate list available?.....	11
Can I have the speakers slides?	11
Can I have a notepad?.....	11
How can I keep up to date with Euroscicon Events?.....	11
I don't want my photograph on any Euroscicon promotional material.....	11
Is there WIFI?.....	11
Can I have a CPD certificate?	11

Agenda (Talk times include 5 – 10 minutes for questions)

Day 1: Diagnosis, Staging and Assessment		
09:00 – 09:45	Exhibitions open	Registration and Refreshments
09:45 – 10:30	Introduction by the Chair Cell-mediated anti-cancer immunotherapy; targeting chemotherapy-resistant malignant cells with personalized immunotherapy mediated by autologous and allogeneic cells	Professor Shimon Slavin, The International Center for Cell Therapy & Cancer Immunotherapy (CTCI), Weizman Center, Tel Aviv, Israel
10:30 – 11:00	Current status of minimally invasive diagnosis and staging of lung malignancies	Dr Jorge Pascual, MD, Assistant Professor, Mayo Clinic College of Medicine, Mayo Clinic, Florida, USA
11:00 – 11:30	Session Break	Speakers' photo, Refreshments, Poster viewing, Sponsors exhibition
11:30 – 12:00	New Imaging Methods for Assessing Tumor Response to Therapy	Dr Richard M. Gore, MD, Professor of Radiology, University of Chicago, Evanston Hospital, Evanston, IL, USA
12:00 – 12:30	Early detection of oral carcinogenesis: the biological fundamentals of in vivo optical imaging	Professor Rui Amaral Mendes, University of Michigan, Michigan, United States
12:30 – 13:00	Oral Presentations	
13:00 – 14:00	Session Break	Lunch, Poster viewing, Sponsors exhibition
14:00 – 14:30	Discussion session	
14:30 – 15:00	Cancer Causation and Risk Communication: The gap between cancer knowledge and community perceptions	Dr Bernard W. Stewart PhD FRACI DipLaw, Professor, Faculty of Medicine, UNSW and Head, Cancer Control Program, South East Sydney Public Health Unit, Locked Bag 88, Randwick, Australia
15:00 – 15:30	Prognostic value of repeat testing in population screening for CRC - for optimizing efficacy	Dr Pavel Elsakov MD PhD, State Reserch Institute, Innovative Medicine Center, Vilnius, Lithuania
15:30 – 16:00	Session Break	Refreshments, Last poster viewing , Last Sponsors exhibition
16:00 – 16:30	Lung Cancer CT Screening : Time for implementation?	Professor John K Field, Director of Research, Roy Castle Lung Cancer Research Programme The University of Liverpool, Cancer Research Centre Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine Roy castle Building, Liverpool, UK
16:30 – 17:00	Novel methods to assess and support older people with cancer; Comprehensive Care for Older People with Cancer (COCOC)	Professor Margot Ann Gosney, University of Reading, Clinical Health Sciences, Reading, UK
17:00	Chairman's Summing Up	Close of Session

Day 2 Session 1: Treatment

09:00 – 09:30	Exhibitions open	Registration and Refreshments
09:30 – 09:40	Introduction by the Chair	TBC
09:40 – 10:00	The Role of Intraoperative Radiation in Retroperitoneal Sarcoma	Dr Richard Gray, Consultant, Section of Surgical Oncology, Mayo Clinic, US
10:00 – 10:20	EWAS and GWAS go together in cancer control	Dr Mukesh Verma , Ph.D, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA
10:20 – 10:40	Breast Cancer, Chemo-resistance and ErbB receptors	Professor Zhixiang Wang , PhD, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada
10:40 – 11:00	Session Break	Speakers' photo, Refreshments, Poster viewing, Sponsors exhibition
11:00 – 11:20	Low-dose aspirin in the prevention and the treatment of cancer: a review of observational and randomised evidence.	Professor Peter Creighton Elwood, Cardiff University, Penylan, Cardiff, United Kingdom
11:20 – 12:10	Oral Presentations	
12:10 – 12:30	1st line chemotherapy in treatment of mCRC: FOLFIRI vs FOLFIRI+bevacizumab - single institution experience.	Dr Zoran Rakusic, MD, PhD, Head of Clinical Ward, Department of Oncology, University of Zagreb, Croatia
12:30 – 12:50	Second line treatments in advanced non-small cell lung cancer	Dr. Mircea Dediu MDPH, Medical Oncology senior consultant, Chief of Medical Oncology Department, Institute of Oncology" Alexandru Trestioreanu" Bucharest, Bucharest, Romania
12:50 – 13:10	Experience of the European Institute of Oncology in the use of intra-operative radiotherapy with electrons (ELIOT)	Dr Simonetta Monti, Senior Assistant, Medico Assistente, Senology Division, Reparto di Senologia, Milano, Italy
13:10 – 13:50	Session Break	Lunch, Poster viewing, Sponsors exhibition
Day 2 Session 1: Quality of life		
13:50 – 14:00	Introduction by the chair	Professor Robert Thomas, Consultant Oncologist, Cranfield University, Bedford and Addenbrooke's Cambridge University, Hospitals, UK
14:00 – 14:20	Measuring Quality of Survival and Impact of Adverse Events on Quality of Life in Metastatic Disease	Stacie Hudgens And Dr. Anna Forsythe
14:20 – 14:40	Nutritional supplement in patients with cancer	Professor Robert Thomas, Consultant Oncologist, Cranfield University, Bedford and Addenbrooke's Cambridge University, Hospitals, UK
14:40 – 15:30	Oral presentations 14:40 – 14:55 MEASURING THE PREVALENCE, SEVERITY AND QUALITY OF LIFE PREDICTORS OF CONCURRENT SYMPTOMS IN CANCER PATIENTS IN JORDAN M. Al Qadire, M. Al Khalaileh Al al-Bayt University, Mafraq 25113, Jordan TBC	
15:30 – 16:00	Session Break	Refreshments, Last poster viewing Last Sponsors exhibition
16:00 – 16:20	Role of balloons, fiducial markers, and spacers for a reliable targeting and an optimized image guided stereotactic body radiotherapy for prostate cancer	Professor. Raymond Miralbell, Chef de service, Service de radio-oncologie, Hôpitaux universitaires de Genève, Genève, Switzerland
16:20 – 16:40	Reproductive health issues in adolescent and young adult cancer survivors	Professor Gwendolyn P. Quinn , Ph.D., University of South Florida, Morsani College of Medicine, Tampa, FL, USA
16:40 – 17:00	Targeted alpha therapy for cancer & the use of radioisotopes	Dr Graeme Melville, Macquarie University, Sydney, Australia
17:00	Chairman's Summing Up	Close of Session

Day 3: Therapeutics

09:00 – 09:45	Exhibitions open	Registration and Refreshments
09:45 – 10:00	Introduction by the Chairs	Dr Sophia Karagiannis, King's College London School of Medicine, Guy's Tower, Guy's Hospital, London and Dr Ann White Antibody and Vaccine Group, Southampton University Hospital, UK
10:00 – 10:30	From cancer genotype to phenotype by proteomics	Associate Professor Janne Lehtio , Karolinska Institutet, SciLifeLab, Stockholm, Sweden
10:30 – 11:00	Vitamin D binding protein-based immunotherapy leads to reversal of the neoplastic phenotype and suppression of oncogene expression.	Dr Marco Ruggiero, Department of Experimental and Clinical Biomedical Sciences, University of Firenze, Firenze, Italy
11:00 – 11:30	Session Break	Speakers' photo, Refreshment, Poster viewing, Sponsors exhibition
11:30 – 12:00	Involvement of key components of wnt signalling in human astrocytic brain tumours	Professor. Dr. sc. Nives Pećina-Šlaus, Department of Biology, Laboratory for Neurooncology, Croatian Institute for Brain Research, Medical School University of Zagreb, Zagreb, Croatia
12:00 – 12:30	Oral Presentations	
12:30 – 13:30	Session Break	Lunch, Poster viewing, Sponsors exhibition
13:30 – 14:00	Discussion session	
14:00 – 14:30	ErbB-targeted CAR T-cell immunotherapy of cancer: a strategy to maximize the window of therapeutic opportunity.	Dr John Maher, Senior Lecturer in Immunology, NIHR Biomedical Research Centre at Guy ¹ 's and St Thomas ¹ NHS Foundation, Trust and King ¹ 's College London, Research Oncology, Division of Cancer Studies, Guy's Hospital campus, St Thomas St, London, United Kingdom
14:30 – 15:00	Overcoming Mechanisms of Therapeutic Resistance in Advanced Castration Resistant Prostate Cancer	Dr Natasha Kyprianou , James F. Hardymon Chair in Urology Research, Professor of Urology, Molecular Biochemistry, Pathology and Toxicology, Combs, Rm 306, University of Kentucky College of Medicine, Lexington, KY, US
15:00 – 15:30	Session Break	Refreshments Last poster viewing Last Sponsors exhibition
15:30 – 16:00	Oral Presentations	
16:00 – 16:30	Talk title to be confirmed	<i>Dr Ian Hastings, TBC</i>
16:30 – 17:00	Androgen Deprivation Therapy for Prostate Cancer	Professor Patricia Tak Hing Tai, University of Saskatchewan, Regina, Saskatchewan, Canada
17:00	Chairman's Summing Up	Close of Meeting

About the Speakers

Day 1

Shimon Slavin, The International Center for Cell Therapy & Cancer Immunotherapy (CTCI), Weizman Center, Tel Aviv, Israel

Shimon Slavin, MD, Professor of Medicine, pioneered the use of personalized anti-cancer immunotherapy mediated by donor lymphocytes and innovative methods for stem cell transplantation for malignant and non-malignant disorders, including treatment of autoimmune diseases and induction of transplantation tolerance to bone marrow and organ allografts. More recently, Slavin pioneered the use of multi-potent mesenchymal stromal cell for regenerative medicine. Slavin authors 4 books, 660 scientific publications and serves on many editorial boards and many national and international advisory boards. Slavin received many international awards in recognition of his contributions for treatment of malignant and non-malignant disorders.

Jorge Pascual, MD, Assistant Professor, Mayo Clinic College of Medicine, Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Florida, USA

Bernard W. Stewart, PhD FRACI DipLaw, Professor, Faculty of Medicine, UNSW and Head, Cancer Control Program, South East Sydney Public Health Unit, Locked Bag 88, Randwick, Australia

Bernard Stewart has an MSc from University of New South Wales (UNSW) and PhD from University of London and is currently Head, Cancer Control Program at South Eastern Sydney Public Health Unit. He has a professorial appointment in Faculty of Medicine, UNSW. His research focus is prevention of cancer attributable to environmental exposures. Professor Stewart is a Fellow of the Royal Australian Chemical Institute and in 2010 was admitted as a lawyer. For International Agency for Research on Cancer (IARC), he has been involved with the IARC Monographs on Carcinogenic Risks program and most recently co-edited World Cancer Report 2014.

Pavel Elsakov, MD PhD, State Research Institute, Innovative Medicine Center, Vilnius, Lithuania

Pavel Elsakov (1957.05.08) M.D, PhD. Lithuania.

Specialist in Gastroenterology and Oncology.

1) Vilnius Centre Polyclinic. Diagnostics Centre.

2) State Research Institute. Innovative Medicine Centre.

In 1995 year (Lithuania) obtained PhD degree.

He is a member of UICC fellows association.

Awarded of UICC found ICRET grants 1992 (Israel), 1997 (Israel), 2003 (France).

Awarded of Nordic Baltic found grants 1994, 1998 years (Denmark).

His main areas of interest are hereditary cancer and colorectal cancer detection and prevention.

He published more than the 50 national and international research publications.

Day 2

Richard Gray, Consultant, Section of Surgical Oncology, Mayo Clinic, US

Dr. Gray is a consultant in the section of surgical oncology and an associate professor of surgery at the Mayo Clinic in Arizona. He trained in surgery at the Mayo Clinic and in surgical oncology at the H. Lee Moffitt Cancer Center. His clinical and research interest include retroperitoneal sarcoma, melanoma, and breast cancer. He has published more than 90 peer-reviewed manuscripts and serves as an associate editor and reviewer for multiple surgical and surgical oncology journals. He has received multiple awards including the Mayo Clinic Distinguished Educator for 2014.

Mukesh Verma, Ph.D., Branch Chief, Methods and Technologies Branch, Program Director. Epidemiology and Genomics Research Program, Division of Cancer Control and Population Sciences. National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA

Dr. Mukesh Verma is a Program Director and Branch Chief in the Methods and Technologies Branch (MTB), Epidemiology and Genomics Research Program (EGRP) of the National Cancer Institute (NCI), National Institutes of Health (NIH). He provides direction in the areas of biomarkers, early detection, risk assessment, epidemiology and prevention of cancer. Dr. Mukesh Verma holds a M.Sc. from Pantnagar University and a Ph.D. from Banaras Hindu University. He has published 137 research articles, book chapters reviews and edited three books in cancer biomarker, epigenetics and epidemiology field. He represents NCI in the NIH Epigenome Roadmap.

Zhixiang Wang, PhD, Department of Medical Genetics, Signal Transduction Research Group, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada

After obtained his PhD, Dr. Wang did his postdoctoral training at University of Toronto. He started his first independent research position as a Career Scientist at Northeastern Ontario Cancer Centre in 1996 and as an Assistant Professor at University of Ottawa in 1997. He moved to the Department of Cell Biology, University of Alberta as an Assistant Professor. He is now a Full Professor at the Department of Medical Genetics, University of Alberta. His research has focused on ErbB receptor-mediated cell signaling, receptor endocytosis, and human cancer.

Peter Creighton Elwood, Cardiff University, Penylan, Cardiff, United Kingdom

For twenty years Elwood worked with Archie Cochrane and succeeded him as Director of an MRC Research Unit. On retirement he was granted an honorary professorship in Cardiff University. Together with Cochrane, Elwood reported the first randomised trial of aspirin prophylaxis in vascular disease in 1974. He continues to have an involvement in work on aspirin prophylaxis of vascular disease and of cancer, and, most recently on aspirin and an increase in the survival of patients with cancer.

Mircea Dediú, MDPhD, Medical Oncology senior consultant, Chief of Medical Oncology Department, Institute of Oncology "Alexandru Trestioreanu" Bucharest, Bucharest, Romania

Dr. Mircea Dediú is the Head of the Medical Oncology Department at the Institute of Oncology Bucharest. He served as Romanian National Representative at ESMO during 2003-2011. He was accepted as full member of ASCO, ESMO, IASLC and EORTC. Dr. Dediú is deeply involved in clinical research, specifically the lung cancer field. His scientific contribution concluded in 42 full text papers published in prestigious international journals like: New England Journal of Medicine, Journal of Clinical Oncology, Annals of Oncology, Lung Cancer, and Journal of BUON. More than 25 personal communications were accepted for presentation (oral or poster) in prestigious international congresses.

Simonetta Monti, Senior Assistant, Medico Assistente, Senology Division, Reparto di Senologia, Milano, Italy

Degree in Medicine and Surgery (09/28/1992) vote with 110/110 degree from the Faculty of Medicine of the University 'of L'Aquila, with a dissertation entitled "The treatment of cancer patients in the terminal phase".

Postgraduate Diploma in General Surgery (11/11/1997) with Honours degree from the School of Specialization in General Surgery at the University 'of L'Aquila, with a thesis entitled "Problems of surgical non-palpable lesions. A new method of preoperative localization with technetium 99m-labeled albumin. "Master's Degree in senology (01/20/2003), from the University 'degli Studi di Milano. From 01.07.1999 to date, serving as Senior Assistant in the Division of Breast European Institute of Oncology in Milan

Robert Thomas, Consultant Oncologist, Cranfield University, Bedford and Addenbrooke's Cambridge University, Hospitals, UK

A Consultant Oncologist at, Bedford and Addenbrooke's, Hospitals.. A Professor at Cranfield University and senior Clinical lecturer at Cambridge University. He treats breast, prostate and bowel cancer with chemotherapy, radiotherapy and biological therapies but is also a stronger advocate of the role of self help and lifestyle strategies to improve well-being and outcome. He is author of the book "Lifestyle and Cancer" and editor of the cancer treatment and lifestyle website cancernet.co.uk.

He has published over a hundred scientific papers and was chief investigator of the double blind randomised controlled trial of a polyphenol / antioxidant rich supplement (Pomi-T) and designed the UK's first level 4 Cancer rehabilitation course for exercise professionals. He is a Media Spokesman and Chair of the Macmillan Cancer support exercise advisory group. In 2001 he was voted Hospital Doctor Magazine "Doctor of the Year" and in 2007 The British Oncology Association "Oncologist of the Year".

Gwendolyn P. Quinn, Ph.D., Senior Member, Director Survey Methods Core, Professor, University of South Florida, Morsani College of Medicine, Tampa, FL, USA

Dr. Quinn is a Senior Member of Moffitt Cancer Center in the Health Outcomes and Behavior Program and Professor at the University Of South Florida College Of Medicine, Department of Oncologic Sciences. She is Director of the Moffitt Survey Methods Core. She is a health psychologist and bioethicist with a research focus on assessing the behavioral determinants of cancer patient's decisions about provider recommendations. Current projects include adult and pediatric oncology health care providers and reproductive health, barriers to clinical trial participation, ethical issues in genetic testing for hereditary cancer and the use of PGD and training researchers and clinician in conducting research with high risk populations.

Graeme Melville, Macquarie University, Sydney, Australia

Dr Graeme Melville was a senior nuclear researcher at St George Hospital in Sydney, Australia. In the past he was a professional tennis player, NASA astrophysics researcher (Magellan Project), university lecturer and government science policy advisor. Dr Melville has worked in a senior position with the Department of Defence and published many papers in astrophysics and nuclear physics as well as being Editor-in-Chief of an international journal. He was the recipient of the 2005 'Physics in Industry Day' award and 2007 'Research Futures Forum' prize. He is currently the Chairman of the Australian Institute of Physics (NSW) and has published two books. His current research involves producing Ac-225 for 'Targeted Alpha Therapy' (TAT) - a new kind of cancer treatment.

Day 3

Janne Lehtio, Karolinska Institutet, SciLifeLab, Stockholm, Sweden

Associate Professor Janne Lehtiö is principle investigator at Karolinska Institutet and head of clinical proteomics platform at Karolinska University Hospital and Science for life Laboratory, Stockholm, Sweden. Dr Lehtiö's major research interest is to improve human proteome analysis and to use this in-depth proteome information to personalize cancer therapy. Lehtiö's group has published number of methods to improve proteome analysis in leading journals and applied these methods in biomarker and disease mechanism studies. He's laboratory is focusing on cancer and clinical sample analysis using so called proteogenomics methods to connect information from genomics and proteomics levels.

Marco Ruggiero, Department of Experimental and Clinical Biomedical Sciences, University of Firenze, Firenze, Italy

Marco Ruggiero holds a PhD in Molecular Biology, is a certified Medical Doctor specialised in Clinical Radiology. He served in the Army as Medical Lieutenant with specific training in chemical, biological and nuclear warfare. He worked at Burroughs Wellcome Co. North Carolina, USA publishing a seminal paper with Nobel Laureate Sir John Vane and at the National Cancer Institute of the NIH in Bethesda, working with Dr. Stuart A. Aaronson and Dr. Peter Duesberg. He has published more than 150 peer-reviewed scientific papers including papers on the immunotherapy of cancer and chronic fatigue syndrome.

Nives Pećina-Šlaus, Department of Biology, Laboratory for Neurooncology, Croatian Institute for Brain Research, Medical School University of Zagreb, Zagreb, Croatia

Nives Pecina-Slaus is full professor at the department of biology and Head of the Laboratory of neurooncology Croatian institute for brain research. She has received her BS in 1990, her MS in 1992, from the University of Zagreb, Faculty of Sciences, and her PhD in the field of molecular oncology in 1998, from Medical School. She was trained at Cold Spring Harbor Laboratory, New York, and at Georgetown University, Washington DC. She was granted 5 scientific projects. Her research has led to more than 100 publications – 49 scientific papers, a book, abstracts and book chapters. Her main fields of research are cancer genetics, Wnt signaling pathway, tumor suppressor genes, oncogenes, genetics of brain tumors. She is a member on editorial boards of Frontiers in Bioscience, Acta Clinica Croatica, Cancer Cell International and Croatian Medical Journal. She teaches medical biology and was mentor on numerous theses. She was awarded three scientific awards, by Croatian Medical Association, by Academy of Medical Sciences and in 2011. She received National Science Award.

John Maher, Senior Lecturer in Immunology, NIHR Biomedical Research Centre at Guy¹s and St Thomas¹ NHS Foundation, Trust and King¹s College London, Research Oncology, Division of Cancer Studies, Guy's Hospital campus, St Thomas St, London, United Kingdom

Dr John is a clinical immunologist and immunopathologist who leads the "CAR Mechanics" research group within King's College London. His research group is focused on the development of adoptive immunotherapy for cancer and other pathologies using CAR engineered and gamma delta T-cells. He is also a consultant immunologist within King's Health Partners and Barnet & Chase Farm NHS Trust.

Natasha Kyprianou, James F. Hardymon Chair in Urology Research, Professor of Urology, Molecular Biochemistry, Pathology and Toxicology, Combs, Rm 306, University of Kentucky College of Medicine, Lexington, KY, US

Dr. Kyprianou is currently a professor of urology, molecular and cellular biochemistry, pathology and toxicology. A leading investigator in prostate cancer research, she is internationally recognized for her seminal contributions to the identification of apoptosis as a mechanism underlying therapeutic response of breast and prostate tumors to hormone treatment. Her research focuses on apoptosis signaling during prostate cancer progression to metastasis, and development of novel molecular therapeutics targeting advanced prostate cancer. Her book entitled "Molecular Exploitation of Apoptosis Pathways in Prostate Cancer" was recently published by Imperial College Press, London, UK.

Patricia Tak Hing Tai, University of Saskatchewan, Regina, Saskatchewan, Canada

Professor Patricia Tai graduated from the University of Hong Kong in 1984 with a gold medal. She started oncologic research in University of Hong Kong. She joined the University of Saskatchewan, Canada since 1998. Her research employed the Saskatchewan Cancer Registry which is among one of the oldest registry in North America, recognized on many occasions by the North American Association with gold medals. She won many awards and was invited speaker in many conferences. She has 115 presentations, 97 abstracts and 107 full publications. She is an UpToDate author on skin cancer.

Discussion Sessions

The discussion sessions are an opportunity for informal questions and answers. This is an ideal opportunity to get advice and opinion from experts in this area. This session is not for questions about specific talks, which can be asked after the speakers session, but for discussing either general topics or specific issues.

Session breaks

All breaks and registrations will take place in the exhibition area where there will be lunch and refreshments.

Please try to visit all the exhibition stands during this event. Not only do our sponsors enable Euroscicon to keep the registration fees competitive, but they are also here specifically to talk to you

Lunch

- All the chicken in our lunch buffet is Halal
- We have a number of dishes that are gluten free
- We have a range of vegetarian dishes which are separated from the meat and fish dishes

Frequently asked questions about our events

Is the delegate list available?

Yes this is available to everyone who attends the event and our sponsors.

It is available in real time. To access the list please just log into your registration details or use the QR code on right of the agenda card which is provided on the day of the event.

You will not be included in this list if you have opted out and you can do this by logging into your registration details. This list will not be sold or ever give out to third parties.

Can I have the speakers slides?

We cannot give out the slides from our speaker's presentations as they are deleted immediately after each event. If you require a particular set of slides please approach the speaker. We will however have a meeting report and you will be emailed when this report is published.

Can I have a notepad?

Notepads and pens are provided in the delegate bags and at the registration desk

How can I keep up to date with Euroscicon Events?

To keep updated on our events and other Life Science News, please sign up for our newsletter at www.eurosciconnews.com

I don't want my photograph on any Euroscicon promotional material

Please let our tech person know

Is there WIFI?

Yes, please ask registration for log in details

Can I have a CPD certificate?

Your CPD certificate will be available after lunch in the exhibition area

Please remember that EuroSciCon is a small independent company with no subsidies from society memberships or academic rates for venues. We try to be as reasonably priced as possible and our delegate rates are substantially lower than comparable commercial meeting organisations

